Tirzepatide for fatty liver is a promising line of research, not an approved use. In a 2024 trial of 190 adults with inflamed, scarred livers, the inflammation cleared without the scarring getting worse in 44% to 62% of people on weekly tirzepatide after a year, versus 10% on placebo. A separate MRI study in people with type 2 diabetes found liver fat fell by about 8 percentage points in a year, from an average near 16%. But neither brand-name version, Mounjaro or Zepbound, is approved to treat liver disease, and the large trial that could change that isn't expected to finish until 2030. Wegovy, a semaglutide product, does carry a U.S. liver indication.
What fatty liver, MASLD and MASH mean now
The names changed in 2023, when an international panel of liver experts agreed on new terms (Rinella et al., Journal of Hepatology 2023). NAFLD is now MASLD, metabolic dysfunction-associated steatotic liver disease: extra fat in the liver in someone with at least one metabolic risk factor, such as excess weight, high blood sugar or high blood pressure. NASH is now MASH, metabolic dysfunction-associated steatohepatitis: fat plus inflammation that is injuring liver cells.
What matters most over the years is fibrosis, or scar tissue, staged from F0 (none) to F4 (cirrhosis). F2 and F3, moderate and advanced scarring, are where the drug trials have focused.
SYNERGY-NASH results: tirzepatide and MASH
The main evidence is SYNERGY-NASH, a phase 2 trial, meaning a mid-sized study run to find the right dose before a large final one (Loomba et al., NEJM 2024). It enrolled 190 adults with MASH and F2 or F3 scarring confirmed by liver biopsy, a small needle sample of liver tissue. They took weekly tirzepatide at 5, 10 or 15 mg, or a placebo, for 52 weeks, then had another biopsy.
| At 52 weeks | Placebo | 5 mg | 10 mg | 15 mg |
|---|---|---|---|---|
| MASH resolved, scarring no worse | 10% | 44% | 56% | 62% |
| Scarring improved one stage or more, MASH no worse | 30% | 55% | 51% | 51% |
On the top dose, about 6 in 10 people had the inflammation clear, against 1 in 10 on placebo. Scarring improved in about half of those on tirzepatide and 3 in 10 on placebo, a real but smaller gap.
Two cautions come from the paper itself. Only 157 of the 190 people had a second biopsy that could be read; the missing results were filled in as if those people had done as well as the placebo group. And the authors concluded that larger, longer trials are needed. A cleaner biopsy is an early marker, not proof that fewer people will reach cirrhosis. The most common side effects were stomach and bowel problems, mostly mild or moderate.
Tirzepatide and liver fat on MRI
In a substudy of the SURPASS-3 trial, 296 adults with type 2 diabetes and signs of a fatty liver, not diagnosed MASH, had their liver fat measured by MRI-PDFF, a scan that estimates what share of the liver is fat (Gastaldelli et al., Lancet Diabetes & Endocrinology 2022).
Liver fat started at an average of about 16%. After 52 weeks it fell by about 8 percentage points on the pooled 10 mg and 15 mg doses, against about 3 points on insulin degludec, a long-acting insulin used as the comparison.
That study measured fat, not inflammation or scarring. A follow-up analysis published online on August 11, 2026 found the drop held in people carrying PNPLA3 I148M, a gene variant strongly linked to fatty liver; its authors call it exploratory (Cusi et al., Liver International 2026).
Is tirzepatide better than semaglutide for fatty liver?
Nobody knows yet: no trial has put the two head to head in liver disease. What differs today is the label. On August 15, 2025, FDA granted Wegovy accelerated approval for adults with MASH and F2 to F3 scarring who do not have cirrhosis (FDA's approval letter); semaglutide for fatty liver walks through that evidence. A different kind of drug, resmetirom (Rezdiffra), has had a U.S. MASH indication since March 2024.
The closest thing to a comparison is a study published online on August 19, 2026 that used a large health-records network to follow adults with type 2 diabetes and overweight or obesity who started one drug or the other (Banerjee et al., Obesity 2026). Over about 17 months, serious liver events, meaning cirrhosis, a failing liver or liver cancer, happened at almost the same rate on each: about 4 per 1,000 people a year. A records study can't prove cause and effect, but it doesn't point to a clear winner.
Is it the weight loss, or the drug?
Nobody has cleanly separated the two for tirzepatide. In the MRI study, bigger drops in liver fat went with more weight and belly-fat loss, which fits weight loss doing much of the work. Tirzepatide works through two gut-hormone receptors, GIP and GLP-1; its results in other conditions are in tirzepatide benefits.
Newer drugs are testing whether another signal adds something. Survodutide, still in trials, acts on GLP-1 and on glucagon, a hormone that tells the liver to burn stored fuel. A secondary analysis of its phase 2 MASH trial, published online in Hepatology on August 3, 2026 and publicized by VCU Health on September 10, split the drug's effect into a weight-loss part and a remainder (Noureddin et al., Hepatology 2026).
In 170 people with F2 or F3 scarring, weight loss accounted for about two-thirds of the effect on MASH resolution but only about a third of the effect on scarring. The authors read that as a hint that glucagon acts on the liver directly. It is an after-the-fact analysis funded by the drug's maker, and it says nothing about tirzepatide itself.
Mounjaro, Zepbound and fatty liver: what the labels say
The current labels, both revised in August 2026, list type 2 diabetes and cardiovascular risk in type 2 diabetes for Mounjaro, and long-term weight reduction and obstructive sleep apnea for Zepbound. Neither lists fatty liver or MASH. The liver comes up in two places: no dose change is recommended for people with reduced liver function, and gallbladder disease, including gallstones, is a listed warning.
Promise's tirzepatide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved, and it doesn't inherit any trial result or indication from the brands. Why compounded tirzepatide is not FDA-approved has the detail. A licensed provider may still prescribe a compounded formulation when it fits the person; that decision is between the patient and the doctor.
What comes next: the SYNERGY-Outcomes trial
Lilly's phase 3 answer is SYNERGY-Outcomes, which tests tirzepatide and its investigational drug retatrutide, each against placebo, in about 4,500 adults with MASLD (ClinicalTrials.gov NCT07165028). People qualify on scans and blood tests rather than a biopsy. The main question is the one patients care about: over roughly four years, do fewer people reach cirrhosis, liver failure, a transplant or death?
As of September 23, 2026, the day this article was written, the registry lists the trial as recruiting, with a start date of October 15, 2025 and an estimated primary completion in August 2030. Until it reports, tirzepatide's liver evidence stays where it is: encouraging, early, and not the basis of any approval.
Tirzepatide for fatty liver: what a prescriber weighs
"Fatty liver" on an ultrasound report is a starting point, not a diagnosis a medicine gets matched to. A prescriber considering tirzepatide looks at why it's being considered, whether weight, blood sugar or both, and at the liver picture: blood tests, any scarring estimate, other causes of liver disease, gallbladder history and alcohol use, which tirzepatide and alcohol covers. SYNERGY-NASH did not include people with cirrhosis.
At Promise, a licensed provider reviews every request, and not everyone qualifies. If tirzepatide is prescribed, the provider sets the dose.
